Tagged with S

Thailand Suthep Namwongsamran, GM of M&H Manufacturing, provides insights into the distinctive model that has allowed M&H to become one of Thailand’s leading domestic pharmaceutical manufacturers. He also outlines the expected development of the M&H’s international strategy and his focus on bringing biosimilars to Thailand via mutually beneficial partnerships.   We…

Taiwan Professor Shih-Hua Lin, president of Taiwan’s National Defense Medical Center, shares an overview of the academic and research environment of the institute as well as its role in cultivating the internationally connected talent that will drive Taiwan’s biomedical industry forward.   We must focus on how we can continue international…

Company Profile As one of the longest-standing multinational companies in Egypt, French pharmaceutical giant Sanofi aims to plays a major role in ensuring access to innovative pharmaceuticals for the Egyptian population through manufacturing locally.   During President Macron’s visit, Sanofi signed a Memorandum of Understanding (MoU) with the Egyptian Ministry of Health…

Thailand Dr Tares Krassanairawiwong, secretary-general of the Thai FDA shares the recent reforms carried out in the hope of facilitating greater patient access to both domestic and internationally-produced treatments. Dr Krassanairawiwong also highlights the institution’s current priorities, including medical cannabis, positioning Thailand as a clinical trials hub, and further developing the…

Taiwan Scott Li, deputy director of H Spectrum, a biotech and talent incubator within the Foxconn group, explains the organization’s history and unique role in supporting Foxconn’s transition into healthcare. Li also shares his insights on the top challenges facing Taiwan’s innovation and entrepreneurial landscape.   H Spectrum is now positioned…

Thailand Sumalee Kristarnin, country president of Novartis Thailand, shares the main initiatives of the affiliate in Thailand to take care of people, employees and patients. She highlights how the key priorities, put in place at the global level, are reflected in the local business, and how Novartis is trying to introduce…

Opinion Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five fundamental pillars to adopting a patient-centric approach.    We know that patient-centricity not only aids better healthcare, it also has…

Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients.   Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…

China Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over 100 companies, some of which have reconsidered listing on the Hong Kong Exchange, wary of the HKEX’s lukewarm performance.  …

Cannabis GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing a trail for other pharmaceutical companies to follow.   With more and more countries moving to legalise medical cannabis and…

Taiwan William Foreman, president of AmCham Taipei, describes the attractiveness and challenges of Taiwan’s business landscape and the implications of US-China relations on the island. Foreman goes on to highlight the key issues facing the chamber’s healthcare members and concludes with a message about the necessary next steps to further enhance…

Puerto Rico Leobardo Hidalgo, who lived in Puerto Rico as a child, recently came back to the island to head commercial operations at the local BMS affiliate, which has been performing remarkably well. He highlights a portfolio of transformational medicines matched with the local team’s patient-centric approach and knowledge of the ecosystem…